CPHI [CHINA PHARMAS,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x March 31, 2011 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC. Delaware 73-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86 898-6681-1730 (China) (Issuer's telephone number, including area code)] [CERTIFICATION I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Frank Waung, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: May 10, 2011 -------------------------------- President and Chief Executive Officer EX-32.1 4 cphi10qex321033111.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: May 10, 2011 --------------------- (principal financial officer and principal accounting officer) EX-32.2 5 cphi10qex322033111.htm]

By | 2016-03-03T19:34:50+00:00 May 10th, 2011|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] 10-Q: FORM 10-Q (Mark One) x March 31, 2011

[FORM 10-Q (Mark One) x March 31, 2011 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC. Delaware 73-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86 898-6681-1730 (China) (Issuer's telephone number, including area code)] [CERTIFICATION I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Frank Waung, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: May 10, 2011 -------------------------------- President and Chief Executive Officer EX-32.1 4 cphi10qex321033111.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: May 10, 2011 --------------------- (principal financial officer and principal accounting officer) EX-32.2 5 cphi10qex322033111.htm]

By | 2016-03-03T19:36:29+00:00 May 10th, 2011|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x March 31, 2011 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMAS, Delaware 73-1564807 (State or other jurisdiction of (IRS Employerorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China570216 +86 898-6681-1730 (China)] [CERTIFICATION I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATION I, Frank Waung, certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:May 10, 2011 -------------------------------- President and Chief Executive Officer cphi10qex321033111.htm 4 EX-32.1] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:May 10, 2011 --------------------- (principal financial officer and principal accounting officer) cphi10qex322033111.htm 5 EX-32.2]

By | 2016-02-07T22:59:51+00:00 May 10th, 2011|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] 10-Q: FORM 10-Q (Mark One) x March 31, 2011

[FORM 10-Q (Mark One) x March 31, 2011 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMAS, Delaware 73-1564807 (State or other jurisdiction of (IRS Employerorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China570216 +86 898-6681-1730 (China)] [CERTIFICATION I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATION I, Frank Waung, certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:May 10, 2011 -------------------------------- President and Chief Executive Officer cphi10qex321033111.htm 4 EX-32.1] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:May 10, 2011 --------------------- (principal financial officer and principal accounting officer) cphi10qex322033111.htm 5 EX-32.2]

By | 2016-02-07T23:00:45+00:00 May 10th, 2011|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] CORRESP: (Original Filing)

[H UNTER T AUBMAN W EISS LLP Louis Taubman (Admitted NY) LTaubman@htwlaw.com Email: May 9, 2011 Division of Corporate Finance 100 F. Street, N.E. Attn: Mr. Wyman Re: Tianyin Pharmaceutical Co., Inc. Form 10-K for the Fiscal Year Ended June 30, 2009 File No. 001-34189 Dear Mr. Wyman: Very truly yours, HUNTER TAUBMAN WEISS LLP Attorney at Law cc: Dr.]

By | 2016-03-27T20:58:58+00:00 May 9th, 2011|Categories: Chinese Stocks, SEC Original, TPI|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] CORRESP: H UNTER T AUBMAN W EISS LLP Louis

[H UNTER T AUBMAN W EISS LLP Louis Taubman (Admitted NY) LTaubman@htwlaw.com Email: May 9, 2011 Division of Corporate Finance 100 F. Street, N.E. Attn: Mr. Wyman Re: Tianyin Pharmaceutical Co., Inc. Form 10-K for the Fiscal Year Ended June 30, 2009 File No. 001-34189 Dear Mr. Wyman: Very truly yours, HUNTER TAUBMAN WEISS LLP Attorney at Law cc: Dr.]

By | 2016-03-27T20:59:53+00:00 May 9th, 2011|Categories: Chinese Stocks, TPI, Webplus ver|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] CORRESP: (Original Filing)

[H UNTER T AUBMAN W EISS LLP Louis Taubman (Admitted NY) LTaubman@htwlaw.com Email: May 3, 2011 Division of Corporate Finance 100 F. Street, N.E. Attn: Mr. Wyman Re: Tianyin Pharmaceutical Co., Inc. Form 10-K for the Fiscal Year Ended June 30, 2009 File No. 001-34189 Dear Mr. Wyman: Very truly yours, HUNTER TAUBMAN WEISS LLP Attorney at Law cc: Dr.]

By | 2016-03-27T21:00:58+00:00 May 3rd, 2011|Categories: Chinese Stocks, SEC Original, TPI|Tags: , , , , , |0 Comments

WX [WuXi PharmaTech (Cayman)] 20-F: TABLE OF CONTENTS Page INTRODUCTION 1 2 PART

[TABLE OF CONTENTS Page INTRODUCTION 1 2 PART I. ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS 3 ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 3 ITEM 3. KEY INFORMATION 3 ITEM 4. INFORMATION ON THE COMPANY 24 ITEM 4A. UNRESOLVED STAFF COMMENTS 42 ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS 42 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND] [LIST OF SUBSIDIARIES • • WX (BVI) Limited, incorporated in the British Virgin Islands. • WuXi AppTec (BVI) Inc., incorporated in the British Virgin Islands. • • Shanghai AppTec(HK) Limited, incorporated in HongKong. • Kaipara Enterprises Limited, incorporated in Cyprus. • Klivia Investments Sp. zo.o., incorporated in Poland. • Klivia Investments Sp. zo.o. Luxembourg Branch, incorporated in Luxembourg. • WuXi] [Certification I, Ge Li, certify that: 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based] [Certification I, Edward Hu, certify that: 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based] [Certification Ge Li Chief Executive Officer EX-13.1 5 dex131.htm CERTIFICATION] [Certification Edward Hu Chief Financial Officer EX-13.2 6 dex132.htm CERTIFICATION] [April 27, 2011 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republic of China RE: WUXI PHARMATECH (CAYMAN) INC. Dear Sirs/Madams, Company We have acted as legal advisors as to the laws of the People’s Republic of China to WuXi PharmaTech (Cayman) Inc., an exempted limited liability company incorporated in the Cayman Islands] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-146730 on Form S-8 and in Registration Statement No. 333-161757 on Form F-3 of our reports dated April 26, 2011, relating to the consolidated financial statements and financial statement schedule of WuXi PharmaTech (Cayman) Inc., and the effectiveness WuXi PharmaTech (Cayman) Inc.’s]

By | 2016-04-02T18:33:52+00:00 April 27th, 2011|Categories: Chinese Stocks, Webplus ver, WX|Tags: , , , , , |0 Comments

WX [WuXi PharmaTech (Cayman)] 20-F: (Original Filing)

[TABLE OF CONTENTS Page INTRODUCTION 1 2 PART I. ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS 3 ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 3 ITEM 3. KEY INFORMATION 3 ITEM 4. INFORMATION ON THE COMPANY 24 ITEM 4A. UNRESOLVED STAFF COMMENTS 42 ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS 42 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND] [LIST OF SUBSIDIARIES • • WX (BVI) Limited, incorporated in the British Virgin Islands. • WuXi AppTec (BVI) Inc., incorporated in the British Virgin Islands. • • Shanghai AppTec(HK) Limited, incorporated in HongKong. • Kaipara Enterprises Limited, incorporated in Cyprus. • Klivia Investments Sp. zo.o., incorporated in Poland. • Klivia Investments Sp. zo.o. Luxembourg Branch, incorporated in Luxembourg. • WuXi] [Certification I, Ge Li, certify that: 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based] [Certification I, Edward Hu, certify that: 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based] [Certification Ge Li Chief Executive Officer EX-13.1 5 dex131.htm CERTIFICATION] [Certification Edward Hu Chief Financial Officer EX-13.2 6 dex132.htm CERTIFICATION] [April 27, 2011 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republic of China RE: WUXI PHARMATECH (CAYMAN) INC. Dear Sirs/Madams, Company We have acted as legal advisors as to the laws of the People’s Republic of China to WuXi PharmaTech (Cayman) Inc., an exempted limited liability company incorporated in the Cayman Islands] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-146730 on Form S-8 and in Registration Statement No. 333-161757 on Form F-3 of our reports dated April 26, 2011, relating to the consolidated financial statements and financial statement schedule of WuXi PharmaTech (Cayman) Inc., and the effectiveness WuXi PharmaTech (Cayman) Inc.’s]

By | 2016-04-02T18:32:31+00:00 April 27th, 2011|Categories: Chinese Stocks, SEC Original, WX|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] CORRESP: (Original Filing)

[H UNTER T AUBMAN W EISS LLP Louis Taubman (Admitted NY) LTaubman@htwlaw.com Email: April 25, 2010 Division of Corporate Finance 100 F. Street, N.E. Attn: Mr. Wyman Re: Tianyin Pharmaceutical Co., Inc. Form 10-K for the Fiscal Year Ended June 30, 2009 File No. 001-34189 Dear Mr. Wyman: Very truly yours, LESER HUNTER TAUBMAN & TAUBMAN Attorney at Law cc:]

By | 2016-03-27T21:04:08+00:00 April 25th, 2011|Categories: Chinese Stocks, SEC Original, TPI|Tags: , , , , , |0 Comments
Skip to toolbar